First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

被引：0
|
作者：
Tianhong Li
Patricia LoRusso
Michael L. Maitland
Sai-Hong Ignatius Ou
Erkut Bahceci
Howard A. Ball
Jung Wook Park
Geoffrey Yuen
Anthony Tolcher
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology
[2] Wayne State University,Karmanos Cancer Institute
[3] University of Chicago Medicine,Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics
[4] University of California Irvine School of Medicine,Chao Family Comprehensive Cancer Center
[5] Astellas Pharma Global Development,undefined
[6] South Texas Accelerated Research Therapies (START) Center for Cancer Care,undefined
[7] Present address: Yale Smilow Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
ASP3026; Neoplasms; ALK inhibitor; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Li, Tianhong
    LoRusso, Patricia
    Maitland, Michael L.
    Ou, Sai-Hong Ignatius
    Bahceci, Erkut
    Ball, Howard A.
    Park, Jung Wook
    Yuen, Geoffrey
    Tolcher, Anthony
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [3] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [4] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    Investigational New Drugs, 2013, 31 : 409 - 416
  • [5] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Tibes, Raoul
    Fine, Gil
    Choy, Gavin
    Redkar, Sanjeev
    Taverna, Pietro
    Oganesian, Aram
    Sahai, Amarpal
    Azab, Mohammad
    Tolcher, Anthony W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 463 - 471
  • [6] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
    Raoul Tibes
    Gil Fine
    Gavin Choy
    Sanjeev Redkar
    Pietro Taverna
    Aram Oganesian
    Amarpal Sahai
    Mohammad Azab
    Anthony W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 463 - 471
  • [7] A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Hamilton, Erika
    Xing, Yan
    Rasco, Drew W.
    Smith, Lon
    Lee, Ya-Li
    Fang, Steven
    Wei, Jiao
    Hui, Ai-Min
    CANCERS, 2022, 14 (20)
  • [8] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [9] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Joerger, Markus
    Calvo, Emiliano
    Laubli, Heinz
    Lopez, Juanita
    Alonso, Guzman
    de la Fuente, Elena Corral
    Hess, Dagmar
    Konig, David
    Perez, Vicky Sanchez
    Bucher, Christoph
    Jethwa, Sangeeta
    Garralda, Elena
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [10] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
12345